Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AFP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human AFP Recombinant Protein His-tagged, High purity (>95%), Endotoxin <1EU/µg, Sequence Verified, HEK293 Expressed (Native Glycosylation) |
View AFP Products |
| Gene Delivery | AFP Lentivirus Particles CMV promoter, High titer (>10^8 TU/mL), for stable HepG2 or 293T cell line construction |
View AFP Products |
| Benchmark Ab | Anti-AFP Neutralizing Antibody (Biosimilar) Recombinant human IgG1, Sequence Verified, for assay standardization |
View AFP Products |
| Validator | AFP siRNA Set (3 sequences) For knockdown verification and specificity control in HCC models |
View AFP Products |
| Related Target: GPC3 | Glypican-3 Co-expressed in 70% AFP+ HCC, synergistic dual-targeting strategy |
View GPC3 Products |
| Related Target: PD-L1 | CD274 (PD-L1) Checkpoint combination partner for AFP-directed immunotherapy |
View PD-L1 Products |
| Related Target: HLA-A | Crucial for AFP peptide presentation in TCR-T/TCRm therapies | View HLA-A Products |
| Related Target: CD3E | Essential for Bispecific T-cell Engager (BiTE) format validation | View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Secreted Antigen Neutralization | High-purity AFP (>95%) with verified endotoxin levels for quantitative binding assays and ELISA standards |
| Cross-species Cyno/Mouse Eval | Human/Mouse/Cyno ortholog proteins available with >95% purity and sequence verification |
| AFP-positive Cell Line Construction | High-titer Lentivirus particles (>10^8 TU/mL) for stable integration in HepG2 or 293T cells |
| False Positives / Specificity Control | Validated siRNA set included for AFP knockdown rescue experiments |
| Family & MHC Specificity | Strict sequence homology verification to exclude cross-reactivity with Albumin (55% homology) and off-target peptide-MHC complexes, essential for TCR/TCRm specificity screening |
Live AFP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AFP-targeted therapeutics is intensifying, with major players shifting focus from traditional diagnostic utilization to direct therapeutic targeting. As first-generation TCR-T therapies and bispecific antibodies enter Phase I/II trials, the next wave of R&D is targeting combination strategies with checkpoint inhibitors and novel modalities that neutralize AFP-mediated immunosuppression. Modern drug discovery increasingly targets intracellularly processed AFP peptides presented by HLA complexes, requiring optimal affinity tuning to balance robust tumor killing with strict safety profiles and avoid off-target cross-reactivity with similar peptide sequences.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Adaptimmune, TC Biopharm, Eureka Therapeutics | HLA-A2+ HCC | Peptide-MHC Tetramer Validation (Need high-purity AFP for antigen processing) |
| Bispecific (AFPxCD3 & TCR-mimic) | Innovative Biotechs, AlloVir | Advanced Solid Tumors | Secreted Antigen Binding & Peptide-MHC Heterodimer Validation (Need conformationally intact recombinant AFP and MHC complexes) |
| Neutralizing mAb | Emerging Biotechs | High-AFP HCC | Functional Blockade Assays (Need soluble AFP for immunosuppression neutralization) |
| Peptide Vaccine | Academic Consortia | Adjuvant HCC | Immunogenicity Testing (Need full-length AFP for epitope mapping) |